MedDataX Logo

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

NCT ID: NCT02238262

Last Updated: 2014-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2318 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micardis®. Observational Study in Patients With Essential Hypertension

NCT02200094

Hypertension
COMPLETED

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

NCT02176850

Hypertension
COMPLETED

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

NCT02242851

Hypertension
COMPLETED

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

NCT02242331

Hypertension
COMPLETED

Pharmacovigilance and Patient Compliance in Hypertensive Patients

NCT02200575

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

essential hypertension patients

Telmisartan

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Micardis® low and high dose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with diagnosis of essential hypertension
* Minimum age of 18 years

Exclusion Criteria

* NA
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.374

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Telmisartan in Mild to Moderate Hypertensive Patients
NCT02260089 COMPLETED PHASE4
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
NCT02248129 COMPLETED
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
NCT00638911 COMPLETED
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
NCT02242318 COMPLETED PHASE4
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
NCT00909038 COMPLETED
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
NCT00168779 COMPLETED PHASE4
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
NCT00240448 COMPLETED PHASE4
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
NCT02177396 COMPLETED PHASE3
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects
NCT02187523 COMPLETED PHASE1
Telmisartan Tab Hypertension
NCT00890084 COMPLETED
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
NCT02261116 COMPLETED PHASE4
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
NCT00034840 COMPLETED PHASE4
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects
NCT02176512 COMPLETED PHASE1
Antihypertensive Medications and the Risk of Sepsis
NCT02248896 COMPLETED
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
NCT04218552 COMPLETED PHASE2
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
NCT02178306 COMPLETED PHASE4
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 COMPLETED
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
NCT05843162 UNKNOWN PHASE4
Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers
NCT02262624 COMPLETED PHASE1
Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers
NCT02262598 COMPLETED PHASE1
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 COMPLETED PHASE3
Hypertension and Cardiovascular Risk Factors
NCT00171782 COMPLETED PHASE4
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00846365 COMPLETED PHASE3
Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers
NCT02262780 COMPLETED PHASE1
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
NCT00996281 COMPLETED PHASE3